Compare AMP & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMP | TAK |
|---|---|---|
| Founded | 1894 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.1B | 43.3B |
| IPO Year | 2005 | N/A |
| Metric | AMP | TAK |
|---|---|---|
| Price | $471.79 | $18.41 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $560.20 | N/A |
| AVG Volume (30 Days) | 789.0K | ★ 3.6M |
| Earning Date | 01-29-2026 | 01-29-2026 |
| Dividend Yield | 1.37% | ★ 2.87% |
| EPS Growth | ★ 39.94 | N/A |
| EPS | ★ 36.43 | 0.45 |
| Revenue | $18,513,000,000.00 | ★ $28,475,252,603.00 |
| Revenue This Year | $2.38 | N/A |
| Revenue Next Year | $5.20 | $0.47 |
| P/E Ratio | ★ $12.83 | $40.87 |
| Revenue Growth | ★ 6.12 | N/A |
| 52 Week Low | $396.14 | $12.99 |
| 52 Week High | $552.43 | $18.45 |
| Indicator | AMP | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 35.37 | 80.23 |
| Support Level | $451.96 | $17.58 |
| Resistance Level | $550.18 | $17.99 |
| Average True Range (ATR) | 18.15 | 0.22 |
| MACD | -7.42 | 0.07 |
| Stochastic Oscillator | 16.68 | 96.51 |
Ameriprise Financial has evolved into a diversified financial services provider that generates roughly 65% of its operating income from advice and wealth management. With nearly $1.2 trillion in segment assets under management and advisory at year-end 2025, and with roughly 10,600 affiliated and employee advisors, Ameriprise is one of the larger US-based wealth managers. It also boasts a reasonably large asset management franchise in Columbia Threadneedle, which boasted $678 billion in assets under management at year-end 2025. The firm's third key segment is its retirement and protection services business, which sells insurance products to the firm's advisory clients. After eliminations, Ameriprise had $1.69 trillion in assets under management and advisory across segments at year-end 2025.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.